Navigation Links
GENFIT: Strong U.S. Exposure for Its Biomarker Activity
Date:1/6/2011

LILLE, France and CAMBRIDGE, Mass., Jan. 6, 2011 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced its presence at two U.S. events: the 28th J.P. Morgan Healthcare Conference (from January 11th to 14th, 2011) and the Biotech Showcase (from January 10th to 12th, 2011).

At these events, the Company will give a progress update on its research programs, in particular those dedicated to the theranostic field, that are based on GENFIT's proprietary microparticle capture and characterization technologies for the identification of novel biomarkers:

- The BMGFT01 program, through a translational approach combining specific preclinical models and clinical cohorts of patients at high cardiovascular risk, is dedicated to the discovery of early markers of atherosclerosis and vulnerable plaque via the analysis of plasmatic microparticle signatures.

-  The BMGFT02 program, in the field of type 2 diabetes and its early stages, aims to identify novel biomarkers of pancreatic beta cell dysfunction, in particular through two major clinical studies (DECODIAB and ABOS) involving the longitudinal follow-up of more than 1000 patients.

Jean-Francois Mouney, Chairman of GENFIT's Management Board, stated: "At a time of intense negotiations for our leading drug candidate GFT505, we are proud to present the significant progress that GENFIT has made on its programs linked to the detection of early biomarkers of diabetes and atherosclerosis. For the past two years, GENFIT has been working on the development of a breakthrough technology in this domain. This technology will provide, on the one hand, a rapid, targeted, and predictive follow-up of the efficacy of new treatments for certain metabolic pathologies, and, on the other hand, new diagnostic solutions for these same diseases at very early stages. In this context, our newsflow in the biomarker area will be particularly active this year."

About GENFIT:GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...).  GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER,...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Items in this press release may contain forward-looking statements involving risks and uncertainties.  The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus.  This press release has been prepared in both French and English languages.  In the event of any differences between the two texts, the French language version shall supersede.Contacts:GENFITJean-Francois Mouney – CEO & Chairman of the Management Board+33 (0)3 2016 4000MILESTONES – Press RelationsBruno Arabian+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.frRusso PartnersMartina Schwarzkopf, Ph.D.+1 212 845-4292 / +1 347 591 8785 - martina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE GENFIT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Medicine Announces Strong Second Quarter 2008 Results
2. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
3. Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability
4. Senetek Affirms Strong Financial Position
5. Strong elasticity size effects in ZnO nanowires
6. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
7. Cephalon Reports Another Strong Quarter
8. Shires New Product Portfolio Delivers Strong Quarterly Performance
9. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
10. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
11. ACORN CRO Continues Growth in Strong Third Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... , ... October 10, 2017 , ... Dr. Bob Harman, ... his local San Diego Rotary Club. The event entitled “Stem Cells ... and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):